Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PIK3CA testing in hormone receptor-positive/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories.
Pepe F, Venetis K, Cursano G, Frascarelli C, Pisapia P, Vacirca D, Scimone C, Rappa A, Russo G, Mane E, Pagni F, Castellano I, Troncone G, Angelis C, Curigliano G, Guerini-Rocco E, Malapelle U, Fusco N. Pepe F, et al. Among authors: venetis k. Pharmacogenomics. 2024 Feb;25(3):161-169. doi: 10.2217/pgs-2023-0238. Epub 2024 Mar 5. Pharmacogenomics. 2024. PMID: 38440825
PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores.
Ivanova M, Frascarelli C, Cerbelli B, Pignataro MG, Pernazza A, Venetis K, Sajjadi E, Criscitiello C, Curigliano G, Guerini-Rocco E, Graziano P, Martini M, d'Amati G, Fusco N. Ivanova M, et al. Among authors: venetis k. Hum Pathol. 2024 Feb;144:22-27. doi: 10.1016/j.humpath.2024.01.008. Epub 2024 Jan 24. Hum Pathol. 2024. PMID: 38278450
Non-Small Cell Lung Cancer Testing on Reference Specimens: An Italian Multicenter Experience.
Pepe F, Russo G, Venuta A, Scimone C, Nacchio M, Pisapia P, Goteri G, Barbisan F, Chiappetta C, Pernazza A, Campagna D, Giordano M, Perrone G, Sabarese G, Altimari A, de Biase D, Tallini G, Calistri D, Chiadini E, Capelli L, Santinelli A, Gulini AE, Pierpaoli E, Badiali M, Murru S, Murgia R, Guerini Rocco E, Venetis K, Fusco N, Morotti D, Gianatti A, Furlan D, Rossi G, Melocchi L, Russo M, De Luca C, Palumbo L, Simonelli S, Maffè A, Francia di Celle P, Venesio T, Scatolini M, Grosso E, Orecchia S, Fassan M, Balistreri M, Zulato E, Reghellin D, Lazzari E, Santacatterina M, Piredda ML, Riccardi M, Laurino L, Roz E, Longo D, Romeo DP, Fazzari C, Moreno-Manuel A, Puglia GD, Prjibelski AD, Shafranskaya D, Righi L, Listì A, Vitale D, Iaccarino A, Malapelle U, Troncone G. Pepe F, et al. Among authors: venetis k. Oncol Ther. 2024 Mar;12(1):73-95. doi: 10.1007/s40487-023-00252-5. Epub 2024 Jan 11. Oncol Ther. 2024. PMID: 38200361 Free PMC article.
Think "HER2" different: integrative diagnostic approaches for HER2-low breast cancer.
Marchiò C, Criscitiello C, Scatena C, Santinelli A, Graziano P, Malapelle U, Cursano G, Venetis K, Fanelli GN, Pepe F, Berrino E, Angelis C, Perrone G, Curigliano G, Fusco N. Marchiò C, et al. Among authors: venetis k. Pathologica. 2023 Dec;115(6):292-301. doi: 10.32074/1591-951X-942. Pathologica. 2023. PMID: 38180137 Free PMC article. Review.
Trop-2 as an Actionable Biomarker in Breast Cancer.
Cursano G, Frigo E, Sajjadi E, Ivanova M, Venetis K, Guerini-Rocco E, Criscitiello C, Curigliano G, Fusco N. Cursano G, et al. Among authors: venetis k. Curr Genomics. 2023 Nov 22;24(3):129-131. doi: 10.2174/1389202924666230726112233. Curr Genomics. 2023. PMID: 38178982 No abstract available.
Multi-omics integrative modelling for stereotactic body radiotherapy in early-stage non-small cell lung cancer: clinical trial protocol of the MONDRIAN study.
Volpe S, Zaffaroni M, Piperno G, Vincini MG, Zerella MA, Mastroleo F, Cattani F, Fodor CI, Bellerba F, Bonaldi T, Bonizzi G, Ceci F, Cremonesi M, Fusco N, Gandini S, Garibaldi C, Torre D, Noberini R, Petralia G, Spaggiari L, Venetis K, Orecchia R, Casiraghi M, Jereczek-Fossa BA. Volpe S, et al. Among authors: venetis k. BMC Cancer. 2023 Dec 15;23(1):1236. doi: 10.1186/s12885-023-11701-9. BMC Cancer. 2023. PMID: 38102575 Free PMC article.
Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study.
Morganti S, Marra A, Gandini S, Ascione L, Ivanova M, Venetis K, Sajjadi E, Zagami P, Giugliano F, Taurelli Salimbeni B, Berton Giachetti PPM, Corti C, De Camilli E, Curigliano G, Fusco N, Criscitiello C. Morganti S, et al. Among authors: venetis k. Eur J Cancer. 2023 Dec;195:113397. doi: 10.1016/j.ejca.2023.113397. Epub 2023 Oct 23. Eur J Cancer. 2023. PMID: 37890353
Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer.
Ivanova M, Porta FM, D'Ercole M, Pescia C, Sajjadi E, Cursano G, De Camilli E, Pala O, Mazzarol G, Venetis K, Guerini-Rocco E, Curigliano G, Viale G, Fusco N. Ivanova M, et al. Among authors: venetis k. Virchows Arch. 2024 Jan;484(1):3-14. doi: 10.1007/s00428-023-03656-w. Epub 2023 Sep 28. Virchows Arch. 2024. PMID: 37770765 Free PMC article. Review.
Immune microenvironment dynamics in breast cancer during pregnancy: impact of gestational age on tumor-infiltrating lymphocytes and prognosis.
Sajjadi E, Venetis K, Ivanova M, Noale M, Blundo C, Di Loreto E, Scarfone G, Ferrero S, Maggi S, Veronesi P, Galimberti VE, Viale G, Peccatori FA, Fusco N, Guerini-Rocco E. Sajjadi E, et al. Among authors: venetis k. Front Oncol. 2023 Aug 21;13:1116569. doi: 10.3389/fonc.2023.1116569. eCollection 2023. Front Oncol. 2023. PMID: 37671051 Free PMC article.
59 results